These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35326692)

  • 1. Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage.
    Alessi I; Caroleo AM; de Palma L; Mastronuzzi A; Pro S; Colafati GS; Boni A; Della Vecchia N; Velardi M; Evangelisti M; Carboni A; Carai A; Vinti L; Valeriani M; Reale A; Parisi P; Raucci U
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system complications of cancer therapy.
    Rinne ML; Lee EQ; Wen PY
    J Support Oncol; 2012; 10(4):133-41. PubMed ID: 22542045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic Complications of Cancer Therapies.
    Lee EQ
    Curr Neurol Neurosci Rep; 2021 Nov; 21(12):66. PubMed ID: 34817688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drugs and the Nervous System.
    Santomasso BD
    Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for astrocytic tumors in children: current and emerging strategies.
    Burzynski SR
    Paediatr Drugs; 2006; 8(3):167-78. PubMed ID: 16774296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues.
    Burns I; Gwynne WD; Suk Y; Custers S; Chaudhry I; Venugopal C; Singh SK
    Front Oncol; 2022; 12():815726. PubMed ID: 35155252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological Complications of Childhood Cancer.
    Weaver L; Samkari A
    Semin Pediatr Neurol; 2017 Feb; 24(1):60-69. PubMed ID: 28779867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review: Neurological Complications From Therapies for Pediatric Brain Tumors.
    Nguyen T; Mueller S; Malbari F
    Front Oncol; 2022; 12():853034. PubMed ID: 35480100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced neurotoxicity in pediatric solid non-CNS tumor patients: An update on current state of research and recommended future directions.
    Sleurs C; Deprez S; Emsell L; Lemiere J; Uyttebroeck A
    Crit Rev Oncol Hematol; 2016 Jul; 103():37-48. PubMed ID: 27233118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cellular immunotherapies in pediatric central nervous system tumors.
    Rumler S
    Front Immunol; 2023; 14():1242911. PubMed ID: 37885882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-treatment-induced neurotoxicity--focus on newer treatments.
    Stone JB; DeAngelis LM
    Nat Rev Clin Oncol; 2016 Feb; 13(2):92-105. PubMed ID: 26391778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good Gone Bad: Complications of Chemotherapy, Immunotherapy, and Radiotherapy on the CNS.
    Mallikarjun KS; Eldaya RW; Miller-Thomas MM; Orlowski HL; Parsons MS
    Curr Probl Diagn Radiol; 2024; 53(1):133-149. PubMed ID: 37495483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central Nervous System Complications Among Oncology Patients.
    Winter SF; Jo J; Schiff D; Dietrich J
    Hematol Oncol Clin North Am; 2022 Feb; 36(1):217-236. PubMed ID: 34607715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic Complications of Conventional Chemotherapy and Radiation Therapy.
    Taylor JW
    Continuum (Minneap Minn); 2023 Dec; 29(6):1809-1826. PubMed ID: 38085899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity.
    Finch EA; Duke E; Hwang EI; Packer RJ
    Pediatr Neurol; 2020 Jun; 107():7-15. PubMed ID: 32113728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological Outcomes of Children Treated for Brain Tumors.
    Pancaldi A; Pugliese M; Migliozzi C; Blom J; Cellini M; Iughetti L
    Children (Basel); 2023 Feb; 10(3):. PubMed ID: 36980030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system injury from novel cancer immunotherapies.
    Winter SF; Vaios EJ; Dietrich J
    Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.